论文部分内容阅读
慢性粒细胞白血病(CML)是一种骨髓增殖性疾病,以携带Ph染色体和(或)BCR-ABL融合基因为特征,编码持续酪氨酸激酶活性的BCR-ABL融合蛋白,导致瘤细胞过多积累[1]。羟基脲、干扰素等传统药物未使患者生存期延长;人类白细胞抗原匹配供者少、移植物抗宿主反应严重等限制了异基因造血干细胞移植的应用[2]。伊马替尼(IM)的出现,为CML患者带来了福音[3]。Kantarjian等[4]回顾分析了
Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by carrying the Ph chromosome and / or the BCR-ABL fusion gene and encoding a BCR-ABL fusion protein that persists tyrosine kinase activity resulting in excessive tumor cells Accumulate [1]. Hydroxyurea, interferon and other traditional drugs did not extend the survival of patients; HLA donors matching less donor-graft-host response and other serious restrictions on allogeneic hematopoietic stem cell transplantation [2]. The emergence of imatinib (IM) has brought gospel to CML patients [3]. Kantarjian et al [4] retrospective analysis